These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2655 related items for PubMed ID: 19027990

  • 1. Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: an open-label pilot study.
    Kubota Y, Yoneda K, Nakai K, Katsuura J, Moriue T, Matsuoka Y, Miyamoto I, Ohya Y.
    J Am Acad Dermatol; 2009 Feb; 60(2):212-7. PubMed ID: 19027990
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of tacrolimus ointment in pediatric Patients with moderate to severe atopic dermatitis.
    Singalavanija S, Noppakun N, Limpongsanuruk W, Wisuthsarewong W, Aunhachoke K, Chunharas A, Wananukul S, Akaraphanth R.
    J Med Assoc Thai; 2006 Nov; 89(11):1915-22. PubMed ID: 17205874
    [Abstract] [Full Text] [Related]

  • 3. Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use.
    Paller AS, Eichenfield LF, Kirsner RS, Shull T, Jaracz E, Simpson EL, US Tacrolimus Ointment Study Group.
    Pediatrics; 2008 Dec; 122(6):e1210-8. PubMed ID: 19015204
    [Abstract] [Full Text] [Related]

  • 4. Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study.
    Schachner LA, Lamerson C, Sheehan MP, Boguniewicz M, Mosser J, Raimer S, Shull T, Jaracz E, US Tacrolimus Ointment Study Group.
    Pediatrics; 2005 Sep; 116(3):e334-42. PubMed ID: 16140675
    [Abstract] [Full Text] [Related]

  • 5. A single-center open-label long-term comparison of tacrolimus ointment and topical corticosteroids for treatment of atopic dermatitis.
    Neumann E, Amtage D, Bruckner-Tuderman L, Mockenhaupt M.
    J Dtsch Dermatol Ges; 2008 Jul; 6(7):548-53. PubMed ID: 18248495
    [Abstract] [Full Text] [Related]

  • 6. 0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial.
    Reitamo S, Harper J, Bos JD, Cambazard F, Bruijnzeel-Koomen C, Valk P, Smith C, Moss C, Dobozy A, Palatsi R, European Tacrolimus Ointment Group.
    Br J Dermatol; 2004 Mar; 150(3):554-62. PubMed ID: 15030341
    [Abstract] [Full Text] [Related]

  • 7. A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis.
    Reitamo S, Ortonne JP, Sand C, Cambazard F, Bieber T, Fölster-Holst R, Vena G, Bos JD, Fabbri P, Groenhoej Larsen C, European Tacrolimus Ointment Study Group.
    Br J Dermatol; 2005 Jun; 152(6):1282-9. PubMed ID: 15948994
    [Abstract] [Full Text] [Related]

  • 8. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children.
    Remitz A, Harper J, Rustin M, Goldschmidt WF, Palatsi R, van der Valk PG, Sharpe G, Smith CH, Dobozy A, Turjanmaa K, European Tacrolimus Ointment Study Group.
    Acta Derm Venereol; 2007 Jun; 87(1):54-61. PubMed ID: 17225017
    [Abstract] [Full Text] [Related]

  • 9. A 4-year follow-up study of atopic dermatitis therapy with 0.1% tacrolimus ointment in children and adult patients.
    Reitamo S, Rustin M, Harper J, Kalimo K, Rubins A, Cambazard F, Brenninkmeijer EE, Smith C, Berth-Jones J, Ruzicka T, Sharpe G, Taieb A, 0.1% Tacrolimus Ointment Long-term Follow-up Study Group.
    Br J Dermatol; 2008 Sep; 159(4):942-51. PubMed ID: 18637898
    [Abstract] [Full Text] [Related]

  • 10. A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis.
    Ling M, Gottlieb A, Pariser D, Caro I, Stewart D, Scott G, Abrams K.
    J Dermatolog Treat; 2005 Aug; 16(3):142-8. PubMed ID: 16096179
    [Abstract] [Full Text] [Related]

  • 11. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis.
    Ruer-Mulard M, Aberer W, Gunstone A, Kekki OM, López Estebaranz JL, Vertruyen A, Guettner A, Hultsch T.
    Pediatr Dermatol; 2009 Aug; 26(5):551-8. PubMed ID: 19840309
    [Abstract] [Full Text] [Related]

  • 12. Health-related utility among adults with atopic dermatitis treated with 0.1% tacrolimus ointment as maintenance therapy over the long term: findings from the Protopic CONTROL study.
    Poole CD, Chambers C, Sidhu MK, Currie CJ.
    Br J Dermatol; 2009 Dec; 161(6):1335-40. PubMed ID: 19754867
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of methylprednisolone aceponate ointment 0.1% compared to tacrolimus 0.03% in children and adolescents with an acute flare of severe atopic dermatitis.
    Bieber T, Vick K, Fölster-Holst R, Belloni-Fortina A, Städtler G, Worm M, Arcangeli F.
    Allergy; 2007 Feb; 62(2):184-9. PubMed ID: 17298428
    [Abstract] [Full Text] [Related]

  • 14. Quality of life in patients with atopic dermatitis: impact of tacrolimus ointment.
    Kawashima M, QOL Research Forum for Patients with Atopic Dermatitis.
    Int J Dermatol; 2006 Jun; 45(6):731-6. PubMed ID: 16796638
    [Abstract] [Full Text] [Related]

  • 15. Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study.
    Thaçi D, Reitamo S, Gonzalez Ensenat MA, Moss C, Boccaletti V, Cainelli T, van der Valk P, Buckova H, Sebastian M, Schuttelaar ML, Ruzicka T, European Tacrolimus Ointment Study Group.
    Br J Dermatol; 2008 Dec; 159(6):1348-56. PubMed ID: 18782319
    [Abstract] [Full Text] [Related]

  • 16. [Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the calcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life].
    Sunderkötter C, Weiss JM, Bextermöller R, Löffler H, Schneider D.
    J Dtsch Dermatol Ges; 2006 Apr; 4(4):301-6. PubMed ID: 16638059
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of tacrolimus 0.03% ointment as second-line treatment for children with moderate-to-severe atopic dermatitis: evidence from a randomized, double-blind non-inferiority trial vs. fluticasone 0.005% ointment.
    Doss N, Kamoun MR, Dubertret L, Cambazard F, Remitz A, Lahfa M, de Prost Y.
    Pediatr Allergy Immunol; 2010 Mar; 21(2 Pt 1):321-9. PubMed ID: 19563466
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids.
    Kirsner RS, Heffernan MP, Antaya R.
    Acta Derm Venereol; 2010 Mar; 90(1):58-64. PubMed ID: 20107727
    [Abstract] [Full Text] [Related]

  • 19. Superiority of tacrolimus 0.1% ointment compared with fluticasone 0.005% in adults with moderate to severe atopic dermatitis of the face: results from a randomized, double-blind trial.
    Doss N, Reitamo S, Dubertret L, Fekete GL, Kamoun MR, Lahfa M, Ortonne JP.
    Br J Dermatol; 2009 Aug; 161(2):427-34. PubMed ID: 19416227
    [Abstract] [Full Text] [Related]

  • 20. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life.
    McKenna SP, Whalley D, de Prost Y, Staab D, Huels J, Paul CF, van Assche D.
    J Eur Acad Dermatol Venereol; 2006 Mar; 20(3):248-54. PubMed ID: 16503881
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 133.